stoxline Quote Chart Rank Option Currency Glossary
  
AbCellera Biologics Inc. (ABCL)
3.615  0.055 (1.54%)    12-08 12:13
Open: 3.66
High: 3.7285
Volume: 1,292,697
  
Pre. Close: 3.56
Low: 3.56
Market Cap: 1,082(M)
Technical analysis
2025-12-08 11:44:05 AM
Short term     
Mid term     
Targets 6-month :  5.52 1-year :  6.54
Resists First :  4.73 Second :  5.59
Pivot price 3.57
Supports First :  3.32 Second :  2.77
MAs MA(5) :  3.55 MA(20) :  3.64
MA(100) :  4.62 MA(250) :  0
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  54.9 D(3) :  43.2
RSI RSI(14): 39.2
52-week High :  6.51 Low :  1.89
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ABCL ] has closed below upper band by 35.1%. Bollinger Bands are 73.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.69 - 3.71 3.71 - 3.73
Low: 3.48 - 3.5 3.5 - 3.53
Close: 3.53 - 3.56 3.56 - 3.6
Company Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Headline News

Fri, 05 Dec 2025
AbCellera Biologics’ Earnings Call: Key Insights - MSN

Fri, 05 Dec 2025
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Fri, 05 Dec 2025
AbCellera Biologics (NASDAQ:ABCL) Nasdaq Today Biotech Pioneer - Kalkine Media

Thu, 04 Dec 2025
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results - Yahoo Finance

Tue, 25 Nov 2025
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss - Yahoo Finance

Tue, 18 Nov 2025
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? - Insider Monkey

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 299 (M)
Shares Float 203 (M)
Held by Insiders 22.9 (%)
Held by Institutions 37.6 (%)
Shares Short 54,440 (K)
Shares Short P.Month 53,200 (K)
Stock Financials
EPS -0.57
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.25
Profit Margin 0 %
Operating Margin -851.8 %
Return on Assets (ttm) -10.5 %
Return on Equity (ttm) -16.9 %
Qtrly Rev. Growth 37.5 %
Gross Profit (p.s.) -0.5
Sales Per Share 0.11
EBITDA (p.s.) -0.78
Qtrly Earnings Growth 0 %
Operating Cash Flow -105 (M)
Levered Free Cash Flow -241 (M)
Stock Valuations
PE Ratio -6.36
PEG Ratio 0
Price to Book value 1.11
Price to Sales 30.71
Price to Cash Flow -10.38
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android